Pharmacology

Action Mechanism of Action Reference
INHIBITOR SLAM family member 7 inhibitor DailyMed
Primary Target
CS1 (CD319)

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Multiple Myeloma 4 D009101 ClinicalTrials
Smoldering Multiple Myeloma 2 D000075122 ClinicalTrials
Amyloidosis, Familial 2 D028226 ClinicalTrials
Leukemia, Plasma Cell 2 D007952 ClinicalTrials
Hematologic Neoplasms 2 D019337 ClinicalTrials
Immunoglobulin G4-Related Disease 2 D000077733 ClinicalTrials

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
15.46
Investigations
10.66
Infections and infestations
9.48
Respiratory, thoracic and mediastinal disorders
7.48
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
6.7
Blood and lymphatic system disorders
6.54
Gastrointestinal disorders
5.68
Cardiac disorders
4.56
Nervous system disorders
4.56
Vascular disorders
4.56
Musculoskeletal and connective tissue disorders
4.4
Injury, poisoning and procedural complications
3.85
Metabolism and nutrition disorders
3.18
Skin and subcutaneous tissue disorders
2.53
Renal and urinary disorders
2.5

Cross References

Resources Reference
CAS NUMBER 915296-00-3
ChEMBL CHEMBL1743010
FDA SRS 1351PE5UGS
Guide to Pharmacology 8361